BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Watanabe R, Zhang H, Berry G, Goronzy JJ, Weyand CM. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 2017;312:H1052-9. [PMID: 28314758 DOI: 10.1152/ajpheart.00024.2017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 57] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Yaseen K, Nevares A, Tamaki H. A Spotlight on Drug-Induced Vasculitis. Curr Rheumatol Rep 2022. [PMID: 36129631 DOI: 10.1007/s11926-022-01088-0] [Reference Citation Analysis]
2 Gosangi B, McIntosh L, Keraliya A, Irugu DVK, Baheti A, Khandelwal A, Thomas R, Braschi-Amirfarzan M. Imaging features of toxicities associated with immune checkpoint inhibitors. Eur J Radiol Open 2022;9:100434. [PMID: 35967881 DOI: 10.1016/j.ejro.2022.100434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lötscher F, Pop R, Seitz P, Recher M, Seitz L. Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases. Curr Rheumatol Rep 2022. [PMID: 35920952 DOI: 10.1007/s11926-022-01083-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Watanabe R, Hashimoto M. Pathogenic role of monocytes/macrophages in large vessel vasculitis. Front Immunol 2022;13:859502. [DOI: 10.3389/fimmu.2022.859502] [Reference Citation Analysis]
5 Les I, Pérez-Francisco I, Cabero M, Sánchez C, Hidalgo M, Teijeira L, Arrazubi V, Domínguez S, Anaut P, Eguiluz S, Elejalde I, Herrera A, Martínez M. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. Front Pharmacol 2022;13:894550. [PMID: 35721217 DOI: 10.3389/fphar.2022.894550] [Reference Citation Analysis]
6 Watanabe R, Hashimoto M. Vasculitogenic T Cells in Large Vessel Vasculitis. Front Immunol 2022;13:923582. [DOI: 10.3389/fimmu.2022.923582] [Reference Citation Analysis]
7 Watanabe R, Hashimoto M. Aging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders. Front Aging Neurosci 2022;14:843305. [DOI: 10.3389/fnagi.2022.843305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Gilon D, Iakobishvili Z, Leibowitz D. The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond. Vaccines 2022;10:304. [DOI: 10.3390/vaccines10020304] [Reference Citation Analysis]
9 Sun L, Zhang W, Zhao L, Zhao Y, Wang F, Lew AM, Xu Y. Self-Tolerance of Vascular Tissues Is Broken Down by Vascular Dendritic Cells in Response to Systemic Inflammation to Initiate Regional Autoinflammation. Front Immunol 2022;13:823853. [PMID: 35154143 DOI: 10.3389/fimmu.2022.823853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Greigert H, Ramon A, Tarris G, Martin L, Bonnotte B, Samson M. Temporal Artery Vascular Diseases. J Clin Med 2022;11:275. [PMID: 35012016 DOI: 10.3390/jcm11010275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kalashnikova LA, Legenko MS, Shabalina AA, Dobrynina LA, Shamtieva KV, Kostyreva MV, Dreval MV, Lesnykh TA. [Primary vasculitis of internal carotid and vertebral arteries: a role of cytokines, transforming growth factor beta 1 and basic fibroblast growth factor]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:14-21. [PMID: 34460152 DOI: 10.17116/jnevro202112107114] [Reference Citation Analysis]
12 Dorst DCHV, Doorn LV, Mirabito Colafella KM, Manintveld OC, Hassing HC, Danser AHJ, Mathijssen RHJ, Versmissen J. Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk? Clin Sci (Lond) 2021;135:1649-68. [PMID: 34283204 DOI: 10.1042/CS20200300] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Bobircă A, Bobircă F, Ancuta I, Florescu A, Pădureanu V, Florescu DN, Pădureanu R, Florescu A, Mușetescu AE. Rheumatic Immune-Related Adverse Events-A Consequence of Immune Checkpoint Inhibitor Therapy. Biology (Basel) 2021;10:561. [PMID: 34203101 DOI: 10.3390/biology10060561] [Reference Citation Analysis]
14 Baldauf MC, Kapauer M, Joerger M, Flatz L, Rodriguez R, Frank S, Felbecker A, Hartmann-Fussenegger S, Hundsberger T. Pembrolizumab-Associated CD8+ Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma. Neurol Neuroimmunol Neuroinflamm 2021;8:e993. [PMID: 33824184 DOI: 10.1212/NXI.0000000000000993] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Zhang C, Yang K, Yang Y, Zhao G. PD-L1 expression on peripheral T-cells and association with coronary heart disease patients: A protocol for systematic reviews and meta-analysis. Medicine (Baltimore) 2021;100:e25157. [PMID: 33761687 DOI: 10.1097/MD.0000000000025157] [Reference Citation Analysis]
16 Neves KB, Montezano AC, Lang NN, Touyz RM. Vascular toxicity associated with anti-angiogenic drugs. Clin Sci (Lond) 2020;134:2503-20. [PMID: 32990313 DOI: 10.1042/CS20200308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
17 Desbois AC, Ciocan D, Saadoun D, Perlemuter G, Cacoub P. Specific microbiome profile in Takayasu's arteritis and giant cell arteritis. Sci Rep 2021;11:5926. [PMID: 33723291 DOI: 10.1038/s41598-021-84725-5] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
18 Baik AH, Tsai KK, Oh DY, Aras MA. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clin Sci (Lond) 2021;135:703-24. [PMID: 33686402 DOI: 10.1042/CS20200331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Greigert H, Zeller M, Putot A, Steinmetz E, Terriat B, Maza M, Falvo N, Muller G, Arnould L, Creuzot-Garcher C, Ramon A, Martin L, Tarris G, Ponnelle T, Audia S, Bonnotte B, Cottin Y, Samson M. Myocardial infarction during giant cell arteritis: A cohort study. Eur J Intern Med 2021;89:30-8. [PMID: 33610415 DOI: 10.1016/j.ejim.2021.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Kim JE, Patel K, Jackson CM. The potential for immune checkpoint modulators in cerebrovascular injury and inflammation. Expert Opin Ther Targets 2021;25:101-13. [PMID: 33356658 DOI: 10.1080/14728222.2021.1869213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Solinas C, Saba L, Sganzerla P, Petrelli F. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. Thrombosis Research 2020;196:444-53. [DOI: 10.1016/j.thromres.2020.09.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
22 Hotta M, Naka G, Minamimoto R, Takeda Y, Hojo M. Nivolumab-Induced Periaortitis Demonstrated by FDG PET/CT. Clin Nucl Med 2020;45:910-2. [PMID: 32701815 DOI: 10.1097/RLU.0000000000003215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Takada K, Hamatake M, Kohashi K, Shimamatsu S, Hirai F, Ohmori S, Tagawa T, Mori M. Limb arteriolar vasculitis induced by pembrolizumab plus chemotherapy in a patient with lung cancer. Int Cancer Conf J 2021;10:83-6. [PMID: 33489708 DOI: 10.1007/s13691-020-00454-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Safi M, Ahmed H, Al-Azab M, Xia YL, Shan X, Al-Radhi M, Al-Danakh A, Shopit A, Liu J. PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. J Adv Res 2021;29:45-54. [PMID: 33842004 DOI: 10.1016/j.jare.2020.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
25 Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. Front Immunol 2020;11:587089. [PMID: 33072134 DOI: 10.3389/fimmu.2020.587089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
26 Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences. Curr Rheumatol Rep 2020;22:68. [PMID: 32845392 DOI: 10.1007/s11926-020-00948-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
27 Watanabe R, Hashimoto M. Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases. Ann Rheum Dis 2020:annrheumdis-2020-217995. [PMID: 32769155 DOI: 10.1136/annrheumdis-2020-217995] [Reference Citation Analysis]
28 Mamlouk O, Lin JS, Abdelrahim M, Tchakarov AS, Glass WF, Selamet U, Buni M, Abdel-Wahab N, Abudayyeh A. Checkpoint inhibitor-related renal vasculitis and use of rituximab. J Immunother Cancer 2020;8:e000750. [PMID: 32718987 DOI: 10.1136/jitc-2020-000750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
29 Stamatis P. Giant Cell Arteritis versus Takayasu Arteritis: An Update. Mediterr J Rheumatol 2020;31:174-82. [PMID: 32676554 DOI: 10.31138/mjr.31.2.174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
30 R Andrade A, Moll-Udina A, Martin R, Cilveti E, Subirà O, Disfetano L, García-Arumí J. Retinal Vasculitis Secondary to Durvalumab. Case Rep Ophthalmol 2020;11:161-6. [PMID: 32508622 DOI: 10.1159/000507609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
31 Melissaropoulos K, Klavdianou K, Filippopoulou A, Kalofonou F, Kalofonos H, Daoussis D. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. Int J Mol Sci 2020;21:E3389. [PMID: 32403289 DOI: 10.3390/ijms21093389] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
32 Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019;115:854-68. [PMID: 30715219 DOI: 10.1093/cvr/cvz026] [Cited by in Crossref: 122] [Cited by in F6Publishing: 173] [Article Influence: 61.0] [Reference Citation Analysis]
33 Parthymos I, Liamis G, Dounousi E, Pentheroudakis G, Mauri D, Zarkavelis G, Florentin M. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. Crit Rev Oncol Hematol 2020;151:102979. [PMID: 32480349 DOI: 10.1016/j.critrevonc.2020.102979] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Desbois AC, Cacoub P, Leroyer AS, Tellier E, Garrido M, Maciejewski-Duval A, Comarmond C, Barete S, Arock M, Bruneval P, Launay JM, Fouret P, Blank U, Rosenzwajg M, Klatzmann D, Jarraya M, Cluzel P, Koskas F, Kaplanski G, Saadoun D. Immunomodulatory role of Interleukin-33 in large vessel vasculitis. Sci Rep 2020;10:6405. [PMID: 32286393 DOI: 10.1038/s41598-020-63042-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
35 Franco F, Méndez M, Gutierrez L, Sanz J, Calvo V, Provencio M. Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma. Immunotherapy 2019;11:379-84. [PMID: 30786844 DOI: 10.2217/imt-2018-0082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
36 Boland P, Heath J, Sandigursky S. Immune checkpoint inhibitors and vasculitis. Current Opinion in Rheumatology 2020;32:53-6. [DOI: 10.1097/bor.0000000000000672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
37 Weiner R, Hanson B, Rehman J, Sun B. Isolated testicular vasculitis due to immune checkpoint inhibitor. Eur J Rheumatol 2020;7:35-6. [PMID: 31782719 DOI: 10.5152/eurjrheum.2019.19061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist 2020;25:6-14. [PMID: 31694890 DOI: 10.1634/theoncologist.2019-0083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
39 Feng J, Ross L, Ontaneda D. Pembrolizumab-Induced CNS Vasculitis: Neurologic Adverse Events Due to Checkpoint Inhibitors. Neurol Clin Pract 2021;11:e30-2. [PMID: 33968488 DOI: 10.1212/CPJ.0000000000000768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Douglas VP, Douglas KA, Cestari DM. Immune checkpoint inhibitors: what neuro-ophthalmologists need to know. Current Opinion in Ophthalmology 2019;30:426-33. [DOI: 10.1097/icu.0000000000000608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS, Fonarow GC, Lenihan DJ, Bhatt DL. Cardiovascular Toxicities of Immune Checkpoint Inhibitors. Journal of the American College of Cardiology 2019;74:1714-27. [DOI: 10.1016/j.jacc.2019.07.079] [Cited by in Crossref: 42] [Cited by in F6Publishing: 62] [Article Influence: 14.0] [Reference Citation Analysis]
42 Crout TM, Lennep DS, Kishore S, Majithia V. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review. Curr Rheumatol Rep 2019;21. [DOI: 10.1007/s11926-019-0828-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
43 Lindner AK, Gruenbacher G, Schachtner G, Thurnher M, Pichler R. Rare, but Severe: Vasculitis and Checkpoint Inhibitors. Eur Urol Focus 2020;6:609-12. [PMID: 31072806 DOI: 10.1016/j.euf.2019.04.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
44 Weyand CM, Watanabe R, Zhang H, Akiyama M, Berry GJ, Goronzy JJ. Cytokines, growth factors and proteases in medium and large vessel vasculitis. Clin Immunol 2019;206:33-41. [PMID: 30772599 DOI: 10.1016/j.clim.2019.02.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
45 Ohnuma K, Hatano R, Dang NH, Morimoto C. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Modern Rheumatology 2019;29:721-32. [DOI: 10.1080/14397595.2018.1532559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
46 Oren O, Herrmann J. Arterial events in cancer patients-the case of acute coronary thrombosis. J Thorac Dis 2018;10:S4367-85. [PMID: 30701104 DOI: 10.21037/jtd.2018.12.79] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
47 Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579-1589. [PMID: 30442497 DOI: 10.1016/s1470-2045(18)30608-9] [Cited by in Crossref: 292] [Cited by in F6Publishing: 399] [Article Influence: 73.0] [Reference Citation Analysis]
48 Misra DP, Naidu GSRSNK, Agarwal V, Sharma A. Vasculitis research: Current trends and future perspectives. Int J Rheum Dis 2019;22:10-20. [DOI: 10.1111/1756-185x.13370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
49 Castillo B, Gibbs J, Brohl AS, Seminario-Vidal L. Checkpoint inhibitor-associated cutaneous small vessel vasculitis. JAAD Case Rep 2018;4:675-7. [PMID: 30112452 DOI: 10.1016/j.jdcr.2018.05.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
50 Kuret T, Burja B, Feichtinger J, Thallinger GG, Frank-Bertoncelj M, Lakota K, Žigon P, Sodin-Semrl S, Čučnik S, Tomšič M, Hočevar A. Gene and miRNA expression in giant cell arteritis-a concise systematic review of significantly modified studies. Clin Rheumatol 2019;38:307-16. [PMID: 30069799 DOI: 10.1007/s10067-018-4231-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 van der Geest KSM, Sandovici M, van Sleen Y, Sanders JS, Bos NA, Abdulahad WH, Stegeman CA, Heeringa P, Rutgers A, Kallenberg CGM, Boots AMH, Brouwer E. Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? Arthritis Rheumatol 2018;70:1366-76. [PMID: 29648680 DOI: 10.1002/art.40520] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
52 Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol 2018;37:2579-84. [PMID: 29923081 DOI: 10.1007/s10067-018-4177-0] [Cited by in Crossref: 85] [Cited by in F6Publishing: 99] [Article Influence: 21.3] [Reference Citation Analysis]
53 Erreni M, Manfredi AA, Garlanda C, Mantovani A, Rovere-Querini P. The long pentraxin PTX3: A prototypical sensor of tissue injury and a regulator of homeostasis. Immunol Rev 2017;280:112-25. [PMID: 29027216 DOI: 10.1111/imr.12570] [Cited by in Crossref: 24] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
54 Padda A, Schiopu E, Sovich J, Ma V, Alva A, Fecher L. Ipilimumab induced digital vasculitis. J Immunother Cancer 2018;6:12. [PMID: 29433584 DOI: 10.1186/s40425-018-0321-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
55 Weyand CM, Berry GJ, Goronzy JJ. The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol 2018;103:565-75. [PMID: 28848042 DOI: 10.1189/jlb.3MA0717-283] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
56 Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis. Circulation 2018;137:1934-48. [PMID: 29254929 DOI: 10.1161/CIRCULATIONAHA.117.030423] [Cited by in Crossref: 73] [Cited by in F6Publishing: 95] [Article Influence: 14.6] [Reference Citation Analysis]
57 Graver JC, Sandovici M, Diepstra A, Boots AMH, Brouwer E. Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries. Ann Rheum Dis 2018;77:e16-e16. [DOI: 10.1136/annrheumdis-2017-211860] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]